A multinational, randomized, phase III trial of XELIRI ( plus bevacizumab) versus FOLFIRI ( plus bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).

被引：0

作者：

Muro, Kei

Kim, Tae Won

Park, Young Suk

Uetake, Hiroyuki

Nishina, Tomohiro

Nozawa, Hiroaki

Matsumoto, Hiroshi

Yamazaki, Kentaro

Han, Sae-Won

Lee, Keun-Wook

Deng, Yanhong

Buyse, Marc E.

Satoh, Taroh

Ryoo, Baek-Yeol

Shen, Lin

Iwasa, Satoru

Morita, Satoshi

Sakamoto, Junichi

Xu, Rui-hua

机构：

[1] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan

[2] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea

[4] Tokyo Med & Dent Univ, Dept Surg Specialties, Tokyo, Japan

[5] Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[6] Univ Tokyo, Dept Surg Oncol, Tokyo, Japan

[7] Tokyo Metropolitan Komagome Hosp, Tokyo, Japan

[8] Shizuoka Canc Ctr, Shizuoka, Japan

[9] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp,Canc Res Inst, Seoul 151, South Korea

[10] Seoul Natl Univ, Coll Med, Bundang Hosp, Seoul, South Korea

[11] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China

[12] Int Inst Drug Dev, Cambridge, MA USA

[13] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan

[14] Beijing Canc Hosp, Beijing, Peoples R China

[15] Natl Canc Ctr, Gastrointestinal Med Oncol Div, 1-1 Tsukiji 5 chome, Tokyo, Japan

[16] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[17] Tokai Cent Hosp, Kakamigahara, Japan

[18] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.tps780

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS780

引用

下载

页数：1

共 50 条

[31] Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
Vera Gorbunova
J. Thaddeus Beck
Ralf-Dieter Hofheinz
Pilar Garcia-Alfonso
Marina Nechaeva
Antonio Cubillo Gracian
Laszlo Mangel
Elena Elez Fernandez
Dustin A. Deming
Ramesh K. Ramanathan
Alison H. Torres
Danielle Sullivan
Yan Luo
Jordan D. Berlin
British Journal of Cancer, 2019, 121 : 429 - 430
[32] Multicenter phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JS']JSWOG-C3 study)
Mori, Y.
Suzuki, N.
Nagasaka, T.
Tanioka, H.
Iwamoto, Y.
Neki, Y.
Yamatsuji, T.
Kobayashi, M.
Nakajima, M.
Ojima, Y.
Ikeda, S.
Kawamoto, K.
Shinozaki, K.
Tsuji, A.
Hinoi, T.
Yamaguchi, Y.
Yamashita, K.
Shimokawa, M.
Okajima, M.
Hazama, S.
ANNALS OF ONCOLOGY, 2017, 28
[33] XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
Dimitrios Pectasides
George Papaxoinis
Konstantine T Kalogeras
Anastasia G Eleftheraki
Ioannis Xanthakis
Thomas Makatsoris
Epaminondas Samantas
Ioannis Varthalitis
Pavlos Papakostas
Nikitas Nikitas
Christos N Papandreou
George Pentheroudakis
Eleni Timotheadou
Angelos Koutras
Joseph Sgouros
Dimitrios Bafaloukos
George Klouvas
Theofanis Economopoulos
Konstantinos N Syrigos
George Fountzilas
BMC Cancer, 12
[34] XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
Pectasides, Dimitrios
Papaxoinis, George
Kalogeras, Konstantine T.
Eleftheraki, Anastasia G.
Xanthakis, Ioannis
Makatsoris, Thomas
Samantas, Epaminondas
Varthalitis, Ioannis
Papakostas, Pavlos
Nikitas, Nikitas
Papandreou, Christos N.
Pentheroudakis, George
Timotheadou, Eleni
Koutras, Angelos
Sgouros, Joseph
Bafaloukos, Dimitrios
Klouvas, George
Economopoulos, Theofanis
Syrigos, Konstantinos N.
Fountzilas, George
BMC CANCER, 2012, 12
[35] A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI plus bevacizumab compared to FOLFIRI plus bevacizumab alone in second line metastatic colorectal cancer
Ulahannan, Susanna
Pelster, Meredith
LoRusso, Patricia
Falchook, Gerald
Wang, Judy
Barve, Minal
Grewal, Jaspreet
Chow, Warren
Henry, Jason
Cecchini, Michael
Subbiah, Vivek
Leabman, Maya
Hernandez, Genevive
Li, Yao
Sinclair, Angus
Wang, Beatrice
Kotturi, Maya
Humke, Eric
Ahern, Sean
Ennis, Leslie
Caruano, Melaine
Agrawal, Sapeck
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[36] A PHASE I/II STUDY OF BI-WEEKLY XELIRI PLUS BEVACIZUMAB FOR PATIENT WITH METASTATIC COLORECTAL CANCER AS SECOND-LINE CHEMOTHERAPY (BIXER STUDY): REPORTS OF INTERIM ANALYSIS OF PHASE II PART
Suenaga, M.
Matsusaka, S.
Shinozaki, E.
Ozaka, M.
Ogura, M.
Chin, K.
Hatake, K.
Mizunuma, N.
Yamaguchi, T.
ANNALS OF ONCOLOGY, 2012, 23 : 130 - 131
[37] Raltitrexed Chemotherapy Regimen Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer: A Prospective Multicenter Phase II Trial
Li, Sheng
Li, Xiaoyou
Zhu, Qianni
Gao, Jin
Zhu, Chunrong
Zhu, Liangjun
CANCER CONTROL, 2024, 31
[38] FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial
Loupakis, Fotios
Cremolini, Chiara
Masi, Gianluca
Lonardi, Sara
Zagonel, Vittorina
Trenta, Patrizia
Tomasello, Gianluca
Ronzoni, Monica
Ciuffreda, Libero
Zaniboni, Alberto
Tonini, Giuseppe
Buonadonna, Angela
Valsuani, Chiara
Chiara, Silvana
Carlomagno, Chiara
Boni, Corrado
Marcucci, Lorenzo
Boni, Luca
Falcone, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
[39] Comparative analysis of the effectiveness of second-line bevacizumab plus chemotherapy in second-line therapy in metastatic colorectal cancer.
Smagulova, Kaldigul
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[40] A PHASE I/II STUDY OF TRI-WEEKLY XELIRI PLUS BEVACIZUMAB FOR JAPANESE PATIENTS WITH MCRC AS SECOND-LINE CHEMOTHERAPY (BIX STUDY)
Yamaguchi, Tatsuro
Hamamoto, Yasuo
Nishina, Tomohiro
Yamazaki, Kentaro
Ura, Takashi
Takako, Nakajima
Goto, Ayumu
Shimada, Ken
Nakayama, Norisuke
Sakamoto, Junichi
Morita, Satoshi
Yamada, Yasuhide
ANNALS OF ONCOLOGY, 2012, 23 : 99 - 99

← 1 2 3 4 5 →